Shanghai Henlius Biotech Equity 2024

Shanghai Henlius Biotech Aktienanalyse

What does Shanghai Henlius Biotech do?

Shanghai Henlius Biotech Inc. was founded in 2010 and has since focused on the development of innovative biopharmaceuticals. The company is headquartered in Shanghai, China and has additional locations in Taiwan, the USA, and Europe. The company has developed a wide portfolio of products that are manufactured based on monoclonal antibodies. These antibodies are produced in the human body and can recognize and attack diseased tissue, making them useful for the treatment of various diseases. Shanghai Henlius Biotech Inc.'s business model is based on an extensive research and development process, ranging from the discovery of a new drug to final product approval. The company utilizes advanced technologies and research facilities to develop innovative therapies. The company specializes in the development of biosimilars and novel biopharmaceuticals. Biosimilars are drugs that are structurally similar to already approved biopharmaceuticals but may differ in some characteristics, such as their precise molecular structure. The company has already launched several biosimilars on the market, including those for the treatment of gynecologic cancer, breast cancer, and rheumatoid arthritis. In addition to biosimilars, the company also focuses on the development of novel biopharmaceuticals. These drugs are typically used for the treatment of rare diseases or cancer where there are limited treatment options available. The company has developed several such products, including antibodies for the treatment of lung cancer and bladder cancer. Shanghai Henlius Biotech Inc. has successfully established itself in the Chinese market in recent years but also operates internationally. The company has partnerships with numerous companies in Asia, Europe, and the USA to distribute its products worldwide. Partners include well-known names such as Accord Healthcare, Sandoz, and Pfizer. Overall, Shanghai Henlius Biotech Inc. is a leading player in the biotechnology industry. The company specializes in the development of high-quality biopharmaceuticals and has the capability to develop and bring innovative therapies to the market. Its business model is based on extensive research and development processes, allowing the company to be innovative and successful in a highly competitive market. Shanghai Henlius Biotech ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Shanghai Henlius Biotech's Equity

Shanghai Henlius Biotech's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Shanghai Henlius Biotech's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Shanghai Henlius Biotech's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Shanghai Henlius Biotech's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Shanghai Henlius Biotech’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Shanghai Henlius Biotech stock

What is the equity of Shanghai Henlius Biotech this year?

Shanghai Henlius Biotech has equity of 2.19 B CNY this year.

What was the equity of Shanghai Henlius Biotech compared to the previous year?

The equity of Shanghai Henlius Biotech has increased/decreased by 33.98% increased compared to the previous year.

What impact does a high equity have on investors of Shanghai Henlius Biotech?

A high equity is advantageous for investors of Shanghai Henlius Biotech as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Shanghai Henlius Biotech?

A low equity can be a risk for investors of Shanghai Henlius Biotech, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Shanghai Henlius Biotech affect the company?

An increase in equity of Shanghai Henlius Biotech can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Shanghai Henlius Biotech affect the company?

A reduction in equity of Shanghai Henlius Biotech can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Shanghai Henlius Biotech?

Some factors that can affect the equity of Shanghai Henlius Biotech include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Shanghai Henlius Biotech so important for investors?

The equity of Shanghai Henlius Biotech is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Shanghai Henlius Biotech take to change the equity?

To change equity, Shanghai Henlius Biotech can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Shanghai Henlius Biotech pay?

Over the past 12 months, Shanghai Henlius Biotech paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Shanghai Henlius Biotech is expected to pay a dividend of 0 CNY.

What is the dividend yield of Shanghai Henlius Biotech?

The current dividend yield of Shanghai Henlius Biotech is .

When does Shanghai Henlius Biotech pay dividends?

Shanghai Henlius Biotech pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Shanghai Henlius Biotech?

Shanghai Henlius Biotech paid dividends every year for the past 0 years.

What is the dividend of Shanghai Henlius Biotech?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Shanghai Henlius Biotech located?

Shanghai Henlius Biotech is assigned to the 'Health' sector.

Wann musste ich die Aktien von Shanghai Henlius Biotech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Shanghai Henlius Biotech from 7/31/2024 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 7/31/2024.

When did Shanghai Henlius Biotech pay the last dividend?

The last dividend was paid out on 7/31/2024.

What was the dividend of Shanghai Henlius Biotech in the year 2023?

In the year 2023, Shanghai Henlius Biotech distributed 0 CNY as dividends.

In which currency does Shanghai Henlius Biotech pay out the dividend?

The dividends of Shanghai Henlius Biotech are distributed in CNY.